Optogenetics is a combination of optics and genetics technology that can be used to activate or inhibit specific cells in tissues. It has been used to treat Parkinson’s disease, epilepsy and neurological diseases, bu...Optogenetics is a combination of optics and genetics technology that can be used to activate or inhibit specific cells in tissues. It has been used to treat Parkinson’s disease, epilepsy and neurological diseases, but rarely Alzheimer’s disease. Adeno-associated virus carrying the CaMK promoter driving the optogenetic channelrhodopsin-2 (CHR2) gene (or without the CHR2 gene, as control) was injected into the bilateral dentate gyri, followed by repeated intrahippocampal injections of soluble low-molecular-weight amyloid-β1–42 peptide (Aβ1–42). Subsequently, the region was stimulated with a 473 nm laser (1–3 ms, 10 Hz, 5 minutes). The novel object recognition test was conducted to test memory function in mice. Immunohistochemical staining was performed to analyze the numbers of NeuN and synapsin Ia/b-positive cells in the hippocampus. Western blot assay was carried out to analyze the expression levels of glial fibrillary acidic protein, NeuN, synapsin Ia/b, metabotropic glutamate receptor-1a (mGluR-1a), mGluR-5, N-methyl-D-aspartate receptor subunit NR1, glutamate receptor 2, interleukin-1β, interleukin-6 and interleukin-10. Optogenetic stimulation improved working and short-term memory in mice with Alzheimer’s disease. This neuroprotective effect was associated with increased expression of NR1, glutamate receptor 2 and mGluR-5 in the hippocampus, and decreased expression of glial fibrillary acidic protein and interleukin-6. Our results show that optogenetics can be used to regulate the neuronal-glial network to ameliorate memory functions in mice with Alzheimer’s disease. The study was approved by the Animal Resources Committee of Jinan University, China (approval No. LL-KT-2011134) on February 28, 2011.展开更多
The feasibility of recavering glutamic acid by ion exchange method with macroporous resins was investigated. Their adsorption properties in static state and the effective factors,such as pH, concentration of feed and ...The feasibility of recavering glutamic acid by ion exchange method with macroporous resins was investigated. Their adsorption properties in static state and the effective factors,such as pH, concentration of feed and the ratio of ammonium ion toglutamic acid,were systematically explored. The best conditions of separating glutamic acid from mother liquid were obtained.展开更多
<p style="margin-left:10.0pt;"> <br /> </p> <p style="margin-left:10.0pt;"> <span>The coenzyme B<sub>12</sub> dependent glutamate mutase is composed of two...<p style="margin-left:10.0pt;"> <br /> </p> <p style="margin-left:10.0pt;"> <span>The coenzyme B<sub>12</sub> dependent glutamate mutase is composed of two apoenzyme proteins subunits;S and E<sub>2</sub>, which while either fused or separate assemble with coenzyme B<sub>12</sub> to form an active holoenzyme (E<sub>2</sub>S<sub>2</sub>-B<sub>12</sub>) for catalyzing the reversible isomerization between (<i>S</i>)-glutamate and (2<i>S</i>, 3<i>S</i>)-3-methylas</span><span>- </span><span>partate. In order to assay the activity of glutamate mutase by UV spectrophotometry, this reaction is often coupled with methylaspartase which deaminates (2<i>S</i>, 3<i>S</i>)-3-methylaspartate to form mesaconate (<i>λ</i><sub>max</sub> = 240 nm, </span><span>Ɛ</span><sub><span>240</span></sub><span> = 3.8 mM<sup>-1</sup>·cm<sup>-1</sup>). The activities of different reconstitutions of glutamate mu<span>tase from separate apoenzyme components S and E in varied amount</span></span><span>s</span><span> of </span><span>coenzyme B<sub>12</sub> and adenosylpeptide B<sub>12</sub> as cofactors were measured by this assay and used to reveal the binding properties of the cofactor by the Michaelis</span><span>- </span><span>Menten Method. The values of <i>K<sub>m</sub></i> for coenzyme B<sub>12</sub> in due to reconstitutions of holoenzyme in 2, 7 and 14 S: E were determined as;1.12 ± 0.04 μM, 0.7 ± 0.05 μM and 0.52 ± 0.06 μM, respectively, so as those of adenosylpeptide B<sub>12</sub>;1.07 ± 0.04 μM and 0.35 ± 0.05 μM as obtained from respective 2 and 14 S: E compositions of holoenzyme. Analysis of these kinetics results curiously as<span>sociate</span></span><span>s</span><span> the increasing affinity of cofactors to apoenzyme with</span><span> </span><span>increased amount of component S used in reconstituting holoenzyme from separate</span><span> apoenzyme components and cofactor.</span><span> Moreover, in these studies a new method for assaying the activity of glutamate mutase was developed, whereby glutamate mutase activity is measured via depletion of NADH (<i>λ</i><sub>max</sub> = 340 nm, </span><span>Ɛ</span><sub><span>340</span></sub><span> = 6.3 mM<sup>-1</sup>·cm<sup>-1</sup>) as determined by UV spectrophotometry after addition of (2<i>S</i>,<span> 3<i>S</i>)-3-methylaspartate and pyruvate to a mixture of E<sub>2</sub>S<sub>2</sub>-B<sub>12</sub> and two auxiliary </span><span>holoenzymes system;pyridoxal-5-phosphate dependent glutamate-pyruvate </span><span>aminotransferase and N</span>ADH dependent (<i>R</i>)-2-hydroxyglutarate dehydrogenas<span>e. The activity of glutamate-pyruvate aminotransferase was relatively complete recovered upon the addition of (<i>S</i>)-glutamate and pyruvate to the mixtures of hologlutamate-pyruvate aminotransferase and (<i>R</i>)-2-hydroxylglutarate</span> dehydrogenase which were incubated with each putative inhibitor of glutamate mutase. Additionally, the new assay was used to determine the kinetic constants of (2<i>S</i>, 3<i>S</i>)-3-methylaspartate in the reaction of glutamate mutase as <i>K</i><sub>m</sub>= 7 ± 0.07 mM and <i>k</i><sub>cat</sub>= 0.54 ± 0.6 s<sup>-1</sup>. Application of Briggs-Haldane formula allowed the calculation of an equilibrium constant of the reversible isomerization, <i>K</i><sub>eq</sub> = [(<i>S</i>)-glutamate] × [(2<i>S</i>, 3<i>S</i>)-3-methylaspartate]<sup>-1</sup> = 16, where the kinetic constants of (<i>S</i>)-glutamate were determined by the standard methylaspartase coupled assay.<span></span></span> </p> <p> <br /> </p>展开更多
OBJECTIVE: To investigate the antiepileptic effects of Chaihushugan decoction(CHSGD) in rats with pentylenetetrazole(PTZ)-induced seizures and to discuss the impact of CHSGD on glutamate metabolism, a hypothesized und...OBJECTIVE: To investigate the antiepileptic effects of Chaihushugan decoction(CHSGD) in rats with pentylenetetrazole(PTZ)-induced seizures and to discuss the impact of CHSGD on glutamate metabolism, a hypothesized underlying mechanism of seizure reduction.METHODS: Fifty Wistar rats were divided randomly into either control(n = 10) or experimental(n = 40)groups. Rats in the control group were administered physiological saline intraperitoneally. A subconvulsive dose of PTZ(35 mg/kg) was administered intraperitoneally to rats in the experimental group to induce seizures. The fully PTZ-kindled rats were then randomly divided into five subgroups(n = 8 each) based on the following treatment categories: physiological saline, VPA(200 mg/kg), CHSGD(2.5 g/kg), CHSGD(5 g/kg), or CHSGD(10 g/kg),administered orally once per day, respectively. On day 28 following initiation of drug treatment, seizures were monitored. The rats were then sacrificed, and hippocampal dissections were performed for subsequent studies.RESULTS: CHSGD significantly prolonged the latency of myoclonic, clonic, and tonic seizures, while decreasing overall seizure rates in the kindled rats.The measured concentrations of 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-d-glucose(2-NBDG) and glutamate were significantly lower in the hippocampi of kindled rats in groups treated with CHSGD compared with those treated with PTZ alone. In addition, CHSGD was found to up-regulate both the expression of glutamate transporter-1(GLT-1) protein and the activity of glutamine synthetase(GS) in the hippocampi of kindled rats.CONCLUSION: These results suggest that CHSGD has antiepileptic effects on PTZ-induced seizures.The results further suggest an increase in glutamate metabolism at the synaptic cleft is a putative underlying mechanism of seizure reduction.展开更多
Objective Muncl8-1 has an important role in neurotransmitter release, and controls every step in the exocy- totic pathway in the central nervous system. In the present study, whether epileptic seizure causes a change ...Objective Muncl8-1 has an important role in neurotransmitter release, and controls every step in the exocy- totic pathway in the central nervous system. In the present study, whether epileptic seizure causes a change of Muncl8 localization in neuronal nuclei was analyzed. Methods Epilepsy models were established by injection of kainic acid （KA） solution into hippocampus of Sprague-Dawley （SD） rats or intraperitoneal injection of KA in Kunming mice. The hippocampal neurons were prepared from embryonic day 18 SD rats, and cultured in neurobasal medium, followed by treatment with glutamate for 3 h. Neuronal and glial nuclei of hippocampus were separated by sucrose density gradient centrifugation. The nucleus-enriched fractions were stained with 0.1% Cresyl Violet for morphological assay. Immuno- chemistry and immunoelectron microscopy with anti-Muncl 8-1 antibody were used to determine the nuclear locatization of Munc 18-1. Immunoblotting was used to detect the protein level of Munc 18-1. Results The localization of Munc 18-1 in nucleus of rat hippocampal neuron was confirmed by immunochemistry, immunoelectron microscopy, and immunob- lotting detection of neuronal nucleus fraction. In animals receiving intrahippocampal or intraperitoneal injection of KA, immunostaining revealed that the expression of Muncl 8-1 decreased in pyramidal cell layer of CA regions, as well as in hilus and granular cell layer of dentate gyrus in hippocampus. Moreover, immunoblotting analysis showed that the expres- sion level of Muncl 8-1 in nucleus fraction of hippocampus significantly decreased in KA-treated animals. The relation- ship between the change of Muncl8-1 expression in neuronal nuclei and neuronal over-activation was also tested in pri- mary cultured neurons. After treatment with 50 ~tmol/L glutamate acid for 3 h, Muncl8-1 level was decreased in nucleus fraction and increased in cytoplasmic fraction of primary cultured neurons. Conclusion These results suggest that excit- atory stimulation can induce the distribution change of Munc 18-1 in neuron, which may subsequently modulate neuronal functions in brain.展开更多
Our previous study together with other inves- tigations have reported that neonatal hypoxia or ischemia induces long-term cognitive through brain inflammation impairment, at least in part and hypomyelination. How- eve...Our previous study together with other inves- tigations have reported that neonatal hypoxia or ischemia induces long-term cognitive through brain inflammation impairment, at least in part and hypomyelination. How- ever, the detailed mechanisms are not fully understood. Here, we used a rodent model of neonatal hypoxia by subjecting postnatal day 0 （P0） rat pups to systemic hypoxia （3.5 h）. We found that neonatal hypoxia increased the glutamate content and initiated inflammatory responses at 4 h and 1 day after hypoxia, caused hypomyelination in the corpus callosum, and impaired hippocampus-dependent learning and memory when assessed 30-60 days after hypoxia. Interestingly, much of the hypoxia-induced brain damage was ameliorated by treatment with the ATP ana- logue 21,3-0-（2,4,6-trinitrophenyl）-adenosine 5^-triphos- phate （TNP-ATP; blocks all ionotropic P2Xl-7 receptors）, whereas treatment with pyridoxalphosphate-6-azophenyl- 2＇,4＇-disulphonic acid （PPADS; inhibits P2X1-3 and P2X5- 7 receptors） was less neuroprotective. Our data indicated that activation of ionotropic ATP receptors might be par- tially, if not fully, involved in glutamate deregulation, neuroinflammation, hypomyelination, and cognitive dys- function after neonatal hypoxia.展开更多
基金supported by the National Natural Science Foundation of China,No.81171191(to LYZ)the Shenzhen Special Fund Project on Strategic Emerging Industry Development of China,No.JCYJ20160422170522075(to LYZ)the Shenzhen Healthcare Research Project of China,No.201601015(to LYZ)
文摘Optogenetics is a combination of optics and genetics technology that can be used to activate or inhibit specific cells in tissues. It has been used to treat Parkinson’s disease, epilepsy and neurological diseases, but rarely Alzheimer’s disease. Adeno-associated virus carrying the CaMK promoter driving the optogenetic channelrhodopsin-2 (CHR2) gene (or without the CHR2 gene, as control) was injected into the bilateral dentate gyri, followed by repeated intrahippocampal injections of soluble low-molecular-weight amyloid-β1–42 peptide (Aβ1–42). Subsequently, the region was stimulated with a 473 nm laser (1–3 ms, 10 Hz, 5 minutes). The novel object recognition test was conducted to test memory function in mice. Immunohistochemical staining was performed to analyze the numbers of NeuN and synapsin Ia/b-positive cells in the hippocampus. Western blot assay was carried out to analyze the expression levels of glial fibrillary acidic protein, NeuN, synapsin Ia/b, metabotropic glutamate receptor-1a (mGluR-1a), mGluR-5, N-methyl-D-aspartate receptor subunit NR1, glutamate receptor 2, interleukin-1β, interleukin-6 and interleukin-10. Optogenetic stimulation improved working and short-term memory in mice with Alzheimer’s disease. This neuroprotective effect was associated with increased expression of NR1, glutamate receptor 2 and mGluR-5 in the hippocampus, and decreased expression of glial fibrillary acidic protein and interleukin-6. Our results show that optogenetics can be used to regulate the neuronal-glial network to ameliorate memory functions in mice with Alzheimer’s disease. The study was approved by the Animal Resources Committee of Jinan University, China (approval No. LL-KT-2011134) on February 28, 2011.
文摘The feasibility of recavering glutamic acid by ion exchange method with macroporous resins was investigated. Their adsorption properties in static state and the effective factors,such as pH, concentration of feed and the ratio of ammonium ion toglutamic acid,were systematically explored. The best conditions of separating glutamic acid from mother liquid were obtained.
文摘<p style="margin-left:10.0pt;"> <br /> </p> <p style="margin-left:10.0pt;"> <span>The coenzyme B<sub>12</sub> dependent glutamate mutase is composed of two apoenzyme proteins subunits;S and E<sub>2</sub>, which while either fused or separate assemble with coenzyme B<sub>12</sub> to form an active holoenzyme (E<sub>2</sub>S<sub>2</sub>-B<sub>12</sub>) for catalyzing the reversible isomerization between (<i>S</i>)-glutamate and (2<i>S</i>, 3<i>S</i>)-3-methylas</span><span>- </span><span>partate. In order to assay the activity of glutamate mutase by UV spectrophotometry, this reaction is often coupled with methylaspartase which deaminates (2<i>S</i>, 3<i>S</i>)-3-methylaspartate to form mesaconate (<i>λ</i><sub>max</sub> = 240 nm, </span><span>Ɛ</span><sub><span>240</span></sub><span> = 3.8 mM<sup>-1</sup>·cm<sup>-1</sup>). The activities of different reconstitutions of glutamate mu<span>tase from separate apoenzyme components S and E in varied amount</span></span><span>s</span><span> of </span><span>coenzyme B<sub>12</sub> and adenosylpeptide B<sub>12</sub> as cofactors were measured by this assay and used to reveal the binding properties of the cofactor by the Michaelis</span><span>- </span><span>Menten Method. The values of <i>K<sub>m</sub></i> for coenzyme B<sub>12</sub> in due to reconstitutions of holoenzyme in 2, 7 and 14 S: E were determined as;1.12 ± 0.04 μM, 0.7 ± 0.05 μM and 0.52 ± 0.06 μM, respectively, so as those of adenosylpeptide B<sub>12</sub>;1.07 ± 0.04 μM and 0.35 ± 0.05 μM as obtained from respective 2 and 14 S: E compositions of holoenzyme. Analysis of these kinetics results curiously as<span>sociate</span></span><span>s</span><span> the increasing affinity of cofactors to apoenzyme with</span><span> </span><span>increased amount of component S used in reconstituting holoenzyme from separate</span><span> apoenzyme components and cofactor.</span><span> Moreover, in these studies a new method for assaying the activity of glutamate mutase was developed, whereby glutamate mutase activity is measured via depletion of NADH (<i>λ</i><sub>max</sub> = 340 nm, </span><span>Ɛ</span><sub><span>340</span></sub><span> = 6.3 mM<sup>-1</sup>·cm<sup>-1</sup>) as determined by UV spectrophotometry after addition of (2<i>S</i>,<span> 3<i>S</i>)-3-methylaspartate and pyruvate to a mixture of E<sub>2</sub>S<sub>2</sub>-B<sub>12</sub> and two auxiliary </span><span>holoenzymes system;pyridoxal-5-phosphate dependent glutamate-pyruvate </span><span>aminotransferase and N</span>ADH dependent (<i>R</i>)-2-hydroxyglutarate dehydrogenas<span>e. The activity of glutamate-pyruvate aminotransferase was relatively complete recovered upon the addition of (<i>S</i>)-glutamate and pyruvate to the mixtures of hologlutamate-pyruvate aminotransferase and (<i>R</i>)-2-hydroxylglutarate</span> dehydrogenase which were incubated with each putative inhibitor of glutamate mutase. Additionally, the new assay was used to determine the kinetic constants of (2<i>S</i>, 3<i>S</i>)-3-methylaspartate in the reaction of glutamate mutase as <i>K</i><sub>m</sub>= 7 ± 0.07 mM and <i>k</i><sub>cat</sub>= 0.54 ± 0.6 s<sup>-1</sup>. Application of Briggs-Haldane formula allowed the calculation of an equilibrium constant of the reversible isomerization, <i>K</i><sub>eq</sub> = [(<i>S</i>)-glutamate] × [(2<i>S</i>, 3<i>S</i>)-3-methylaspartate]<sup>-1</sup> = 16, where the kinetic constants of (<i>S</i>)-glutamate were determined by the standard methylaspartase coupled assay.<span></span></span> </p> <p> <br /> </p>
基金Supported by Guangdong Natural Science Foundation(The effects of "Treatment from Gan"on Regulation of A-type Potassium Channels by KChIP/Kv4 in the pathomechanism of Refractory Epilepsy,No.2014A030310052)National Natural Science Foundation of China(Study on Regulation of A-type Potassium Channels by KChIP/Kv4 in the Pathomechanism of Refractory Epilepsy and the Effects of "Treatment from Gan",No.81503564)
文摘OBJECTIVE: To investigate the antiepileptic effects of Chaihushugan decoction(CHSGD) in rats with pentylenetetrazole(PTZ)-induced seizures and to discuss the impact of CHSGD on glutamate metabolism, a hypothesized underlying mechanism of seizure reduction.METHODS: Fifty Wistar rats were divided randomly into either control(n = 10) or experimental(n = 40)groups. Rats in the control group were administered physiological saline intraperitoneally. A subconvulsive dose of PTZ(35 mg/kg) was administered intraperitoneally to rats in the experimental group to induce seizures. The fully PTZ-kindled rats were then randomly divided into five subgroups(n = 8 each) based on the following treatment categories: physiological saline, VPA(200 mg/kg), CHSGD(2.5 g/kg), CHSGD(5 g/kg), or CHSGD(10 g/kg),administered orally once per day, respectively. On day 28 following initiation of drug treatment, seizures were monitored. The rats were then sacrificed, and hippocampal dissections were performed for subsequent studies.RESULTS: CHSGD significantly prolonged the latency of myoclonic, clonic, and tonic seizures, while decreasing overall seizure rates in the kindled rats.The measured concentrations of 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-d-glucose(2-NBDG) and glutamate were significantly lower in the hippocampi of kindled rats in groups treated with CHSGD compared with those treated with PTZ alone. In addition, CHSGD was found to up-regulate both the expression of glutamate transporter-1(GLT-1) protein and the activity of glutamine synthetase(GS) in the hippocampi of kindled rats.CONCLUSION: These results suggest that CHSGD has antiepileptic effects on PTZ-induced seizures.The results further suggest an increase in glutamate metabolism at the synaptic cleft is a putative underlying mechanism of seizure reduction.
基金supported by grants from the National Natural Science Foundation of China (No. 81071017, 30470536, 90919004)
文摘Objective Muncl8-1 has an important role in neurotransmitter release, and controls every step in the exocy- totic pathway in the central nervous system. In the present study, whether epileptic seizure causes a change of Muncl8 localization in neuronal nuclei was analyzed. Methods Epilepsy models were established by injection of kainic acid （KA） solution into hippocampus of Sprague-Dawley （SD） rats or intraperitoneal injection of KA in Kunming mice. The hippocampal neurons were prepared from embryonic day 18 SD rats, and cultured in neurobasal medium, followed by treatment with glutamate for 3 h. Neuronal and glial nuclei of hippocampus were separated by sucrose density gradient centrifugation. The nucleus-enriched fractions were stained with 0.1% Cresyl Violet for morphological assay. Immuno- chemistry and immunoelectron microscopy with anti-Muncl 8-1 antibody were used to determine the nuclear locatization of Munc 18-1. Immunoblotting was used to detect the protein level of Munc 18-1. Results The localization of Munc 18-1 in nucleus of rat hippocampal neuron was confirmed by immunochemistry, immunoelectron microscopy, and immunob- lotting detection of neuronal nucleus fraction. In animals receiving intrahippocampal or intraperitoneal injection of KA, immunostaining revealed that the expression of Muncl 8-1 decreased in pyramidal cell layer of CA regions, as well as in hilus and granular cell layer of dentate gyrus in hippocampus. Moreover, immunoblotting analysis showed that the expres- sion level of Muncl 8-1 in nucleus fraction of hippocampus significantly decreased in KA-treated animals. The relation- ship between the change of Muncl8-1 expression in neuronal nuclei and neuronal over-activation was also tested in pri- mary cultured neurons. After treatment with 50 ~tmol/L glutamate acid for 3 h, Muncl8-1 level was decreased in nucleus fraction and increased in cytoplasmic fraction of primary cultured neurons. Conclusion These results suggest that excit- atory stimulation can induce the distribution change of Munc 18-1 in neuron, which may subsequently modulate neuronal functions in brain.
基金supported by grants from the National Natural Science Foundation of China(81200939 and31260242)National Science and Technology Supporting Plan of China(2014BAI01B00)+3 种基金Natural Science Foundation of Yunnan Province,China(2011FB060)the National Undergraduate Innovation Fund of China(201310678001)the Undergraduate Innovation Fund of Yunnan Province,China(6011202105)Department of Pathology and Pathophysiology, School of Basic Medical Science, Kunming Medical University for his support throughout the study
文摘Our previous study together with other inves- tigations have reported that neonatal hypoxia or ischemia induces long-term cognitive through brain inflammation impairment, at least in part and hypomyelination. How- ever, the detailed mechanisms are not fully understood. Here, we used a rodent model of neonatal hypoxia by subjecting postnatal day 0 （P0） rat pups to systemic hypoxia （3.5 h）. We found that neonatal hypoxia increased the glutamate content and initiated inflammatory responses at 4 h and 1 day after hypoxia, caused hypomyelination in the corpus callosum, and impaired hippocampus-dependent learning and memory when assessed 30-60 days after hypoxia. Interestingly, much of the hypoxia-induced brain damage was ameliorated by treatment with the ATP ana- logue 21,3-0-（2,4,6-trinitrophenyl）-adenosine 5^-triphos- phate （TNP-ATP; blocks all ionotropic P2Xl-7 receptors）, whereas treatment with pyridoxalphosphate-6-azophenyl- 2＇,4＇-disulphonic acid （PPADS; inhibits P2X1-3 and P2X5- 7 receptors） was less neuroprotective. Our data indicated that activation of ionotropic ATP receptors might be par- tially, if not fully, involved in glutamate deregulation, neuroinflammation, hypomyelination, and cognitive dys- function after neonatal hypoxia.
